Introduction
SHIP is an inositol polyphosphate 5-phosphatase that has been identified by its association with the adapter protein Shc after stimulation of hematopoietic cells by a variety of hematopoietic growth factors. 1 Cloning of SHIP cDNAs revealed a src homology 2 (SH2) 1 domain at the amino terminus, an inositol polyphosphate 5-phosphatase domain in the central region, two consensus sequences for interacting with phosphotyrosine binding domains (ie NPXY) and proline-rich regions at the carboxy terminus. [2] [3] [4] The selectivity of SHIP in hydrolyzing 5′-phosphates from inositolphosphates and phosphoinositides phosphorylated at the D3-position of the inositol ring, ie Ins(1,3,4,5)P 4 and PtdIns(3,4,5)P 3 , respectively, suggests a direct role for SHIP in the down-regulation of the signalling pathways associated with these second messengers. Evidence for implicating SHIP in the down-regulation of cytokine receptor signal transduction comes from the intriguing phenotype of the SHIP knockout mouse which showed increased numbers of granulocyte-macrophage (GM) progenitors in bone marrow and spleen, an extensive infiltration of lungs with macrophages and a hyperresponsiveness to IL-3, SCF and colony-stimulating factors, ie GM-CSF and CSF-1. 5, 6 Expression of SHIP is detected in early embryogenesis at the onset of hematopoiesis and is restricted in the mouse embryo to hematopoietic cells. 7 In adult mice and humans, expression of SHIP has been detected at different levels in all hematopoietic cells analyzed, including immature CD34 + cells, B cells, T cells, monocytes and granulocytes. 7, 8 Western blot analysis of hematopoietic cell lines and primary hematopoietic cells revealed the existence of several SHIP or SHIP-related proteins. 3, 8, 9 Ectopic expression of full-length SHIP cDNA in fibroblasts, COS cells or DA-ER cells has indicated that a protein of approximately 145 kDa represents a full-length SHIP protein, which often appears as a doublet in SDS gels. 4, 9, 10 However, a protein of 100 kDa was the major SHIP protein detected in human bone marrow and peripheral blood mononuclear cells 8 and a protein of 110 kDa was the major SHIP protein detected in murine bone marrow cells. 5, 9 Further analysis revealed that smaller SHIP proteins of 110 to 125 kDa are generated by proteolytic cleavage at the carboxy terminus and it was hypothesized that these C-terminal-truncated forms of SHIP are generated in vivo and perform distinct functions in hematopoietic cells. 9 In this report, we demonstrate that the 145 kDa form of SHIP is the major SHIP protein expressed in vivo in all hematopoietic cells analyzed. These include peripheral blood mononuclear cells, bone marrow cells and highly enriched CD34 + cells. Our data further indicate that C-terminal-truncated SHIP proteins of approximately 100 to 120 kDa are generated by a PMSF-sensitive protease during cell lysis in vitro.
Materials and methods

Cells
The GM-CSF-dependent human erythroleukemia cell line TF-1 was obtained from T Kitamura.
11 TF-1 cells were cultured in RPMI 1640 medium (GIBCO-BRL, Eggenstein, Germany) supplemented with 10% (v/v) fetal calf serum (FCS) and 440 U/ml recombinant human GM-CSF (Leukomax; Sandoz, Nü rnberg, Germany). The multipotent FDC-Pmix A4 12 and FDC-Pmix 15S 13 were maintained in Iscove's modified Dulbecco's medium (GIBCO-BRL) supplemented with IL-3 and 20% horse serum. The factor-dependent cell lines FDC-P1 and FDC-P1(M) (clone #4) 14 were obtained from D Metcalf (Walter and Eliza Hall Institute, Melbourne, Australia) and TM Dexter (Paterson Laboratories, Manchester, UK), respectively, and were maintained in modified Eagle's medium with 10% FCS and IL-3. FDC-P1 and FDC-P1(M) cells differ in their responsiveness to GM-CSF and in the expression of cell surface markers (CS and C Laker; unpublished results). IL-3-independent mutants from FDC-P1(M) cells were established after retroviral infection and selection in medium without IL-3 (C Stocking, C Laker, M-J Franz and W Ostertag, unpublished results). The factor-dependent cell line 32D 15 was obtained from JS Greenberger and maintained in RPMI supplemented with 10% FCS and IL-3. The factor-dependent cell line DA-1 16 was obtained from J Ihle and cultured in Iscove ‡s modified Dulbecco's medium with 10% FCS and IL-3. Conditioned medium from cells transfected with a bovine papilloma virus vector carrying the IL-3 gene was used as a source of IL-3 at concentrations necessary for maximal proliferation. Starvation and stimulation of FDC-P1 and FDC-P1(M) cells or FDCPmix and DA-1 cells was performed, as decribed previously. 17 Normal human bone marrow and peripheral blood mononuclear cells were obtained from healthy donors. Leukemia cells were obtained from the peripheral blood of patients with acute myeloid leukemia after informed consent. The diagnosis in each case was made by morphology, cytochemistry and surface antigen analysis. Mononuclear cells from blood and bone marrow samples were prepared by gradient sedimentation using Histopaque-1077 according to the manufacturer (Sigma, Deisenhofen, Germany). After gradient sedimentation of peripheral blood cells from leukemia patients the percentage of blasts was more than 90% in each sample analyzed.
CD34
+ progenitor cells were enriched from human bone marrow mononuclear cells from normal donors by magnetic cell separation using the MACS progenitor cell isolation kit (Miltenyi Biotec, Bergisch-Gladbach, Germany) as described previously. 18 The percentage of CD34 + -enriched cells was more than 95% as determined by FACS analysis. Murine bone marrow cells were freshly isolated by rinsing femurs of CD1 mice with phosphate-buffered saline and cells were collected by centrifugation.
RNA analysis
Isolation of RNA and Northern blot analysis were performed as described previously. 19, 20 The filters were exposed to X-ray RX films (Fuji, Dü sseldorf, Germany) for 24 h using an intensifying screen. The size of the mRNAs was estimated by using an RNA marker (RNA ladder; Gibco-BRL). For hybridization we used a murine full-length SHIP cDNA kindly provided by Dr L Rohrschneider.
Preparation of cell lysates
Cells were lysed in Nonidet P40 (NP 40) lysis buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 1% (v/v) NP 40, 2 mM EDTA, 10% (v/v) glycerol, 50 mM sodium fluoride, 10 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM Pefabloc (4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride; Boehringer Mannheim, Mannheim, Germany) and 200 KIU/ml aprotinin (ICN, Eschwege, Germany)). Alternatively, cells were lysed by adding boiling sodium dodecyl sulfate (SDS) buffer (10 mM Tris-HCl, pH 7.4, 1% SDS, 1 mM sodium orthovanadate, 0.1 mM Na-molybdate, 1 mM PMSF) on the cell pellet and the cell extract was incubated for another 5 min at 100°C. If the protein extract was viscous it was pushed several times through a thin syringe. Insoluble material was removed by centrifugation at 4°C for 10 min at 14 000 g. Protein concentration was determined using the detergent compatible BioRad protein assay according to the manufacturer (BioRad, Mü nchen, Germany), and cell lysates were stored in liquid nitrogen until used. In some experiments Leukemia cell extracts from different cells were combined after cell lysis in a ratio of 1:1 or 1:10 and incubated for 15 min on ice before freezing in liquid nitrogen. Additional protease inhibitors used in some experiments as indicated in the figure legends were phenylmethylsulfonyl fluoride (PMSF; Ͼ1 mmol/l; Sigma), N-␣-tosyl-L-lysine chloromethyl ketone (TLCK; 1 mmol/l; Boehringer Mannheim) and E64 (10 g/ml; Boehringer Mannheim).
Antibodies and protein analysis
Cell lysates were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (PAGE) and Western blot analysis as described, previously. 21, 22 Rabbit polyclonal anti-SHIP serum directed against the SH2 domain of murine SHIP was prepared by immunizing rabbits with a glutathione-S-transferase fusion protein corresponding to residues 7-133 of the murine SHIP SH2 domain (Ab 2). Two goat polyclonal antisera directed against peptides corresponding to the N-terminus or C-terminus of murine SHIP were purchased from Santa Cruz Biotechnology (Ab1 and Ab3, respectively). The N-terminal antibody (V-19, SC1963) is directed against the amino acids 5-24 and the C-terminal antibody (M-14; SC-1964) is directed against amino acids 1175-1188 of murine SHIP. Antibodies directed againts MAP-kinases ErK1 and ErK2 and secondary antibodies coupled to horse radish peroxidase were purchased from Santa Cruz Biotechnology. Filters were developed using the ECL system (Amersham). Reprobing of nitrocellulose membrane was performed after antibodies were removed from the nitrocellulose membrane by incubation in stripping buffer (62.5 mM Tris, pH 6.7, 2% SDS and 100 mM ␤-mercaptoethanol) for 30 min at 70°C.
Peptide synthesis and HPLC analysis
The peptide synthesizer used was the semi-automated Biolynx 4175 from LKB. Peptide synthesis was started with 0.1 mmol of the first amino acid coupled to the resin which were bought from Bachem (Heidelberg, Germany), Novabiochem (Bad Soden, Germany) or PE Biosystems (Weiterstadt, Germany). Amino acids were coupled according to the given sequence by adding an excess of 0.25 mmol Fmoc amino acid in each case. Activation used PyBOP [benzotriazole-1-yl-oxytris (pyrrolidino) phosphonium hexafluorophosphate] or HBTU [2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoro phosphate] and ethyldiisopropylamine in DMF.
The following six peptides corresponding to the amino acid (aa) sequence of human SHIP 23 were synthesized ISDPE-YLLDQHIL (hSHIP-1, aa 790-802), SDSDESYGEGCIAL (hSHIP-2, aa 808-821), ETQLPIYTPLTHHG (hSHIP-3, aa 827-840), TREKLYDFVKTERD (hSHIP-4, aa 859-872), NPN YMGVGPFGPPMPLHV (hSHIP-5, aa 911-928), DQQPTAWS-YDQPPKD (hSHIP-6, aa 935-949). 0.02 milligrams of each peptide were incubated for 1 h at room temperature with 5 g of NP 40-solubilized cell extract. Cell extracts of FDC-P1 or FDC-P1(M) cells were prepared as described above, but without the protease inhibitor PMSF and stored at −80°C until used. The peptides and their cleavage products were then analyzed and fractionated by reverse phase high performance liquid chromatography (HPLC) for further analysis by mass spectrometry. The HPLC equipment consisted of two LC9A pumps, an SCL-6B system controller, Sil-6B auto-injector, SPD-6AV UV-Vis spectrophotometer, all from Shimadzu (Duisburg, Germany). Registration and integration was done with Eurochrom software from Knauer (Berlin, Germany). The column was an Alltima C18, 5 , 250 × 4.6 mm from Alltech (Unterhaching, Germany). The column temperature was set to 25°C and controlled by a column thermostat from WO Electronics (Langenzersdorf, Austria). After deprotection, the crude peptide was purified using reversed phase HPLC with a common elution system based on water/acetonitrile/0.1% trifluoroacetic acid.
Mass spectrometry
Positive-ion electrospray ionization mass spectrometry (ESI-MS) was performed, as described previously. 24, 25 Briefly, a Finnigan MAT 95 double focussing sector field mass spectrometer (Bremen, Germany) fitted with an analytica of Branford (Branford, CT, USA) electrospray ionization source was used. The mass spectrometer was set to a resolution of 1000 and scanned from mass 300 to mass 2300 in 2.8 s; acceleration voltage was 5 kV. The spray voltage was 3 kV. Samples were dissolved in methanol/0.1% HCOOH 1:1 (v/v) and were introduced into the ion source by injecting 10 l aliquots into a constant carrier flow of the same solvent as carrier solvent (3 l/min) using an infusion pump (Harvard, South Natick, USA). Compressed air was used as sheath gas and drying gas.
Results
Different forms of SHIP are detected in FDC-P1 and FDC-P1(M) cells
To analyze the expression of SHIP in hematopoietic cells on the protein level, we performed Western blot experiments with total cell lysates using anti-SHIP antibodies directed against the SH2 domain located at the N-terminus of SHIP. As shown in Figure 1a , a 102 kDa protein is detected in FDC-P1 cells whereas proteins of 195, 145 and 135 kDa are detected in FDC-P1(M) cells. The 145 kDa protein was the major SHIP protein expressed in FDC-P1(M) cells and had the same apparent size as the full-length p145 SHIP protein described previously. 4, 9, 10 The 135 kDa protein may be identical to the 135 kDa isoform of SHIP with an internal deletion of 61 amino acids due to alternative splicing described recently by Lucas and Rohrschneider. 26 However, the 195 kDa protein, which was detectable with the anti-SHIP-SH2 antiserum, was not detectable with two other sera directed against peptides, either from the C-terminus of SHIP or from the N-terminus of SHIP ( Figure 1d ) and did not bind to the SH3 domain of Grb2 in a pull-down experiment with glutathione-S-transferase fusion protein (data not shown). Therefore, p195 most likely does not represent an isoform of SHIP, but rather a protein containing a SH2 domain crossreacting with the anti-SHIP-SH2 antiserum. Further analysis of seven IL-3-independent mutants of FDC-P1(M) cells revealed the appearance of the 102 kDa SHIP form and additional bands up to 120 kDa in several clones with the concomitant reduction of the 145 and 135 kDa SHIP proteins (Figure 1a ). These data indicated that different forms of SHIP are detectable in FDC-P1 cells, FDC-P1(M) cells and factor-independent FDC-P1(M) mutants.
To analyze whether the expression of different forms of SHIP proteins is due to the expression of different RNAs we performed a Northern blot analysis with total RNAs isolated from FDC-P1, FDC-P1(M) and the seven IL-3-independent FDC-P1(M) mutants as well as RNA from other hematopoietic cell lines, ie FDC-Pmix clone A4, FDC-Pmix clone 15S, DA-1 and 32D and from primary murine bone marrow cells for expression of SHIP mRNA. In all hematopoietic samples analyzed, a SHIP-specific mRNA of 5 kb was detected (data not shown). Because all these cell lines express the same major 5 kb SHIP mRNA, it seems unlikely that the 102 kDa form of SHIP is the result of alternative splicing, as described for the 135 kDa form of SHIP. 26 The reduction of full-length SHIP proteins in the cells in which the 102 to 120 kDa SHIP forms were detectable suggests rather that smaller forms of SHIP are generated by proteolytic cleavage from larger SHIP proteins, as has been described in other hematopoietic cell lines. 
p102
SHIP is generated by proteolytic cleavage by a PMSF-sensitive protease
The putative involvement of a protease expressed in FDC-P1 cells in generating the 102 kDa form of SHIP by proteolytic cleavage of larger SHIP proteins was analyzed by using protease inhibitors. In additon to the protease inhibitors Pefabloc and aprotinin, which were added routinely to the lysis buffer, we tested the protease inhibitors PMSF, TLCK and E-64. Protein lysates were then analyzed by Western blotting using the anti-SHIP-SH2 antiserum. As shown in Figure 1b SHIP from TF-1 cells into a 102 kDa form. This proteolytic cleavage could be partly inhibited by PMSF (Figure 1c ). These data indicate that the 102 kDa form of SHIP detected in FDC-P1 cells is generated, at least in part, by proteolytic cleavage by a serine protease from larger SHIP forms and that the protease from FDC-P1 cells is able to cleave both murine and human SHIP.
Proteolytic cleavage of p145 SHIP occurs during cell lysis in vitro
We further analyzed whether the proteolytic cleavage of SHIP in FDC-P1 cells occurs in vivo or during the preparation of cell extracts in vitro. To inactivate all protease activity during the preparation of cell extracts immediately, we lysed FDC-P1 cells directly in boiling SDS buffer. The protein lysates were then analyzed with the anti-SHIP antibody directed against a peptide at the N-terminus of SHIP. As shown in Figure 1d , direct lysis of FDC-P1 cells in boiling SDS buffer resulted in the appearence of p145 SHIP and p135 SHIP , whereas p102 SHIP was no longer detectable. These data indicate that FDC-P1 cells express the 145 and 135 kDa forms of SHIP in By using an antibody against a peptide from the C-terminus of SHIP, the proteolytically cleaved form of 102 kDa was no longer detectable in FDC-P1 cells (compare lanes 1 and 5 in Figure 1d ) or in a factor-independent mutant (clone #7) of FDC-P1(M) cells (compare the right lane in Figure 1a and lane 9 in Figure 1d ). The immunoblot analysis with the C-terminal anti-SHIP antibody of lysates from FDC-P1 and FDC-P1(M) cells prepared in boiling SDS buffer did not reveal SHIP proteins other than the 145 and 135 kDa isoforms of SHIP (Figure 1d, lanes 6 and 8) . These data indicate that p102 SHIP is a C-terminal-truncated form of SHIP.
Leukemia
Murine and human bone marrow cells express the 145 and 135 kDa isoforms of SHIP
The existence of a protease activity in FDC-P1 cells that generated small SHIP proteins in vitro prompted us to prepare cell extracts with boiling SDS buffer from murine bone marrow cells. Cell extracts from murine bone marrow cells prepared either with NP 40 or with boiling SDS-buffer (SDS/100°C) were analyzed by immunoblotting with the anti-SHIP-SH2 antibody (Figure 2a) In addition, we analyzed human bone marrow cells from healthy donors for the expression of SHIP proteins. Mononuclear cells from bone marrow were purified by Ficoll gradient and CD34 + cells were enriched to 95% by using a magnetic cell sorter (MACS). Cell extracts from total bone marrow cells and from CD34 + -enriched cells were lysed in boiling SDS buffer and analyzed by immunoblotting with the anti-SHIP-SH2 antibody. In total human bone marrow cells and CD34 + -enriched cells expression of p145 SHIP was detectable (Figure 2b ) whereas p135 SHIP was expressed in these cells at a very low level detectable after long exposure only (data not shown). Similar to the results obtained with murine bone marrow cells, NP 40-solubilized cell extracts from human bone marrow cells resulted in the detection of the 102 kDa form of SHIP (data not shown). We further analyzed human PBMC from six healthy donors for expression of SHIP by immunoblot analysis. As shown in Figure 2c , expression of p145 SHIP was detectable in NP 40-solubilized cell extracts from all human PBMC. p135 SHIP was expressed in some PBMC at a very low level, detectable after long exposure only (data not shown).
Finally, we analyzed cell extracts from PBMC from three patients with acute myeloid leukemia prepared either in NP 40 lysis buffer or in hot SDS buffer by immunoblotting with the anti-SHIP-SH2 antibody. In the PBMC of two patients, ie No. 1 and No. 3, expression of p145 SHIP and a weak expression of p135 SHIP were detectable in cell extracts prepared either in NP 40 lysis buffer or in hot SDS buffer (Figure 2d ). However, in the PBMC of patient No. 2 the 102 kDa proteolytic cleavage product of SHIP was detectable in NP 40-solubilized extracts (Figure 2d) . Lysis of the cells from the same patient in hot SDS buffer resulted in the detection of larger amounts of p145 SHIP whereas p102 SHIP was no longer detectable (Figure 2d ). These data indicate that p145 SHIP and low amounts of p135 SHIP are expressed in PBMC from normal donors and patients with acute myeloid leukemia as well as in murine and human bone marrow cells including CD34 + -enriched cells.
Identification of a proteolytic cleavage site in the carboxy terminus of SHIP between tryptophan residue 941 and serine residue 942
To further characterize the protease which cleaves p145 SHIP we wanted to identify the site of proteolytic cleavage. As shown in Figure 1d, p102 SHIP is truncated at the C-terminus.
Using this result we roughly calculated that a C-terminaltruncated SHIP protein of 102 kDa consists of the first 900 amino acids of the 1188 amino acids of full-length SHIP. To identify the proteolytic cleavage site in SHIP we prepared six peptides (hSHIP-1 to hSHIP-6) located between amino acids 790 and 950 in human SHIP. As a source of the protease which cleaves SHIP we used a NP 40-solubilized protein extract from FDC-P1 cells. Each of the SHIP peptides was incubated with 5 g protein extract and the peptides and their cleavage products were then analyzed by reverse phase HPLC. The HPLC chromatograms of the peptide hSHIP-6 (935-949) after incubation with a protein extract from FDC-P1 cells for 1 min and for 1 h is shown in Figure 3a and b, respectively. The peak of peptide hSHIP-6 had a retention time of 37.67 min (Figure 3a) . After incubation of hSHIP-6 with protein extracts from FDC-P1 cells for 1 h proteolytic cleavage of peptide hSHIP-6 was detectable as measured by the reduction of the peak of hSHIP-6 at 37.67 min and the appearance of two new cleavage products with a retention time of 23.37 and 37.17 min (Figure 3b ). NP 40-solubilized protein extracts from FDC-P1(M) cells, which do not contain proteolytic activity for SHIP, did not show any protease activity for the same peptide (data not shown). Incubation of SHIP peptides hSHIP-1 to hSHIP-5 with protein extracts from FDC-P1 cells did not result in any cleavage as determined by HPLC analysis (data not shown).
To localize the exact position of the cleavage site in hSHIP-6 the cleaved peptides were fractionated by HPLC and the
Figure 3
Proteolytic cleavage of the peptide 935 to 949 of human SHIP. Five g NP 40-solubilized cell extract from FDC-P1 cells prepared without the protease inhibitor PMSF was added to the peptide hSHIP-6 (DQQPTAWSYDQPPKD) corresponding to amino acids 935 to 949 of the human SHIP protein. The reaction was either stopped immediately (a) or stopped after incubation for 1 h at room temperature (b). The peptide and its cleavage products were then analyzed by reversed phase HPLC. The uncleaved peptide (retention time of 37.67 min) and two cleavage products (retention times of 23.37 and 37.17 min) were collected for mass spectrometry.
Leukemia molecular weights of the two fragments resulting from peptide cleavage were determined by mass spectrometry. The mass spectrum for the uncleaved peptide hSHIP-6 (aa 935-949) is shown in Figure 4a . The mass spectrum is characteristic for electrospray ionization with doubly and triply charged ions and clustering of alkali metal ions for the higher charge state of this acidic peptide (Figure 4a) . The experimental molecular weight of hSHIP-6 was determined as 1774.8 Da which matches exactly the predicted molecular weight of the uncleaved peptide (Figure 4a) . The experimental molecular weights of the enzymatic fragments are 844.9 Da for the 23.37 min peak (Figure 4b ) and 948.1 Da for the 37.17 min peak (Figure 4c) . Taking a typical mass accuracy of better than 0.1% this can be explained, only, with a cleavage C-terminal to tryptophan residue 941 giving rise to a fragment 935-941 with a calculated molecular weight of 844.4 Da and a corresponding fragment 942-949 with a calculated molecular weight of 948.4 Da. Thus, proteolytic cleavage of SHIP occurs Leukemia between tryptophan residue 941 and serine residue 942 (Figure 5a ). The location of the cleavage site in the human SHIP protein is shown in Figure 5b .
Discussion
Stimulation of cytokine receptors induces the activation of several intracellular proteins which leads to survival, proliferation or differentiation of hematopoietic cells. Several proteins which become activated in cytokine-stimulated cells have been identified and integrated into signalling pathways like the Jak/STAT pathway, the Ras/Raf/MAP-kinase pathway and Phosphatidylinositol 3-kinase/protein kinase B-pathway. How this 'positive signalling' is turned off has been partly elucidated by the identification of negative regulators of cytokinemediated signalling. At least four types of proteins which exert their effects by different mechanisms have been implicated in this 'negative signalling' and all of them comprise an SH2 domain, indicating that tyrosine phosphorylated proteins are the key targets for their action. These negative regulators of cytokine signalling have been identified as tyrosine phosphatases, eg SHP-1/HCP, 27 as competitors to STAT-binding to the activated receptor, eg CIS, 28, 29 as inhibitors of Jaks, eg JAB, SOCS or SSI [30] [31] [32] and as inositol 5-phosphatases, eg SHIP. 2, 4 SHIP has been implicated in Fc␥RIIB receptor-mediated negative signalling in B cells and mast cells 33 and in the downregulation of cytokine signal transduction in myeloid cells. [4] [5] [6] Expression of several forms of SHIP has been described in hematopoietic cells and SHIP forms of 100-110 kDa were found as the major SHIP proteins expressed in bone marrow and peripheral blood mononuclear cells. 5, 8, 9 Our data presented in this report indicate that p145 SHIP is the major SHIP protein expressed in all hematopoietic samples analyzed, including bone marrow and peripheral blood cells.
In a first analysis of the expression of SHIP in hematopoietic cells we used our regular lysis buffer containing the protease inhibitors Pefabloc, aprotinin, leupeptin and pepstatin to prepare NP 40-solubilized protein extracts. By using this buffer we detected full-length p145 SHIP and a 135 kDa SHIP isoform in the murine cell line FDC-P1(M), whereas a smaller SHIP protein of 102 kDa was detected in FDC-P1 cells. In several factor-independent mutants of FDC-P1(M) cells we detected a reduction in the amount of the 145 and 135 kDa SHIP proteins which was accompanied by the appearance of smaller SHIP bands of 102-120 kDa. These data suggested that the larger SHIP isoforms are cleaved by a protease to generate smaller SHIP proteins as described by Damen et al. 9 The existence of a protease which can cleave p145 SHIP and p135 SHIP in FDC-P1 cells was demonstrated by mixing NP 40-solubilized protein extracts from FDC-P1 and FDC-P1(M) cells which resulted in the conversion of p145 SHIP and p135 SHIP to p102 SHIP . The protease was able to cleave both murine and human SHIP proteins. Further characterization of this protease with several protease inhibitors, ie PMSF, Pefabloc, aprotinin, leupeptin, TLCK, E64 and pepstatin or by the additon of EDTA revealed that its activity could only be inhibited by adding saturating concentrations of PMSF (Ͼ1 mM). These results suggest that the protease which cleaves SHIP belongs to the class of serine proteases, but not to the class of aspartic proteases, cysteine proteases or metalloproteases. Addition of saturating concentrations of PMSF in the lysis buffer during the preparation of NP 40-solubilized cell extracts could partly inhibit the protease activity and allowed the detection of p145 SHIP and p135 SHIP in FDC-P1 cells. By using a fast lysis method with boiling SDS, which inactivates any protease activity within seconds, we were then able to demonstrate that p102 SHIP which was detected in NP 40-solubilized extracts of FDC-P1 cells disappeared completely and p145 SHIP and p135 SHIP were now the only SHIP proteins detectable. These data indicated that FDC-P1 cells express p145 SHIP and p135 SHIP in vivo and that smaller SHIP proteins of 100 to 120 kDa are generated by a PMSF-sensitive protease during the preparation of cell extracts in vitro.
By inhibiting the protease activity with boiling SDS lysis buffer we were then able to detect full-length p145 SHIP in all hematopoietic samples analyzed. These included several murine and human hematopoietic cell lines, primary murine and human bone marrow cells, a CD34 + -enriched fraction of human bone marrow cells, human PBMC from normal donors and PBMC from patients with acute myeloid leukemia. Preparation of NP 40-solubilized protein extracts from the same cells revealed proteolytic cleavage of SHIP in human and murine bone marrow cells and in the leukemia cells of one out of three patients with AML, but not in PBMC of six normal donors. These data strongly suggest that the protease which cleaves full-length SHIP is more expressed or more active in undifferentiated than in differentiated hematopoietic cells. This is of interest with respect to a recent publication in which a SHIP protein of 110 kDa was detected in a NP 40-solubilized cell extract of undifferentiated bone marrow cells, but expression of 145 and 135 kDa SHIP forms were detected in differentiated bone marrow cells. 26 Our data indicate that undifferentiated bone marrow cells and highly enriched CD34 + cells express the 145 and 135 kDa forms of SHIP already prior to induction of differentiation. The reported expression of the 110 kDa SHIP protein in undifferentiated bone marrow cells is most likely the result of the high activity of the protease which cleaves SHIP during the preparation of NP 40-solubilized extracts of bone marrow cells. Therefore, our data do not support a differential expression of smaller and larger SHIP isoforms of 110 kDa or 145/135 kDa, respectively, during hematopoietic differentiation.
In most of the hematopoietic samples, we detected a weak to moderate expression of a 135 kDa protein reacting with antisera directed against the SH2 domain of SHIP. This 135 kDa protein was also detectable with two additional antisera directed against peptides at the N-and C-terminus of SHIP strongly suggesting that the 135 kDa protein is an isoform of SHIP with an internal deletion. In lysates prepared in hot SDS lysis buffer we detected the 135 kDa SHIP protein indicating that this isoform of SHIP is expressed in vivo. A 135 kDa isoform of SHIP has been recently identified by Lucas and Rohrschneider 26 as the product of an alternatively spliced SHIP cDNA. This p135 SHIP protein has an internal deletion of 61 amino acids C-terminal to the first NPXY motif. The proteolytic cleavage site which we identified in SHIP at tryptophan residue 941 is located within the 61 amino acids deleted in this p135 SHIP protein, thereby excluding its proteolytic cleavage at this site. However, we observed the proteolytic cleavage of the 135 kDa SHIP protein, suggesting that either another cleavage site exists in p135 SHIP or that the 135 kDa form of SHIP we describe in this report is a different form of SHIP without a deletion of the region surrounding the cleavage site.
C-terminal-truncated SHIP forms of 125 and 110 kDa have been described by Damen and coworkers. 9 They have shown that a 110 kDa form of SHIP can be generated from the 145 kDa full-length SHIP protein by digestion with calpain in vitro and have hypothesized that these C-terminal truncated forms of SHIP may perform distinct functions within hematopoietic cells. 9 We have confirmed the existence of C-terminaltruncated SHIP forms in NP 40-solubilized cell extracts and have identified a proteolytic cleavage site in SHIP between tryptophan residue 941 and serine residue 942 in an in vitro analysis. A SHIP protein consisting of the first 941 aa has a predicted size of 106 kDa and is therefore close in size to the C-terminal-truncated SHIP protein detected in SDS-PAGE of bone marrow and of the myeloid cell line FDC-P1, which had an apparent molecular weight of 102 kDa. However, our data indicate that these C-terminal-truncated forms of SHIP are generated in vitro during the preparation of cell extracts by proteolytic cleavage from the 145 and 135 kDa forms of SHIP, as described above in detail. The activation of proteolytic cleavage of SHIP during cell lysis may be due to the destruction of cell compartments harboring proteases by the detergent in the lysis buffer, thereby releasing the protease in the cell extract where it can cleave SHIP. Since we could not detect any C-terminal-truncated SHIP proteins in cell extracts Leukemia made with boiling SDS buffer, we have no indication that they exist in vivo. Therefore, our data do not support a physiological role of C-terminal-truncated forms of SHIP, although trace amounts of C-terminal-truncated forms of SHIP may be present in intact cells below the level of detection in our analysis.
In a B cell line, Kavanaugh and coworkers 3 detected the expression of a 110 kDa form of SHIP (which they called SIP), which lacks the SH2 domain, and suggested that this 110 kDa form is a splice variant of p145 SHIP . Immunoblotting of cellular extracts from myeloid cell lines and murine bone marrow cells with an antiserum directed against the C-terminus of SHIP did not reveal the expression of any SHIP proteins other than p145 SHIP and p135 SHIP . Thus, our data do not support the expression of N-terminal-truncated SHIP forms in murine bone marrow and in myeloid cell lines at the detection level of our assay.
We have shown in this report that the 145 and 135 kDa forms of SHIP are expressed in vivo in all hematopoietic cells analyzed, whereas C-terminal-truncated forms of SHIP are generated by a PMSF-sensitive protease during preparation of cell extracts. Our results underline the physiological function of full-length p145 SHIP and a 135 kDa SHIP isoform for signal transduction in bone marrow and peripheral blood cells from normal donors and patients with acute myeloid leukemia.
